121 results on '"Bratland, Åse"'
Search Results
2. High-dose loco-regional pattern of failure after primary radiotherapy in p16 positive and negative head and neck squamous cell carcinoma – A DAHANCA 19 study
3. Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma – A DAHANCA 19 study
4. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
5. Current aspects of the quality of head and neck cancer care – survey of the Scandinavian Society for Head and Neck Oncology.
6. Diagnosis of locally recurrent head and neck squamous cell carcinoma in the Nordic HNC centers and feasibility of the Odense-Birmingham definition
7. 483: Clinical outcomes after dose painting of head and neck cancer with poor prognosis
8. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
9. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
10. KEYNOTE-630: Phase 3 Study of Adjuvant Pembrolizumab in High-Risk Locally Advanced (LA) Cutaneous Squamous Cell Carcinoma (cSCC)
11. Head and neck cancer management in the Nordic countries: an effort to harmonize treatment
12. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
13. Merkel cell carcinoma
14. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
15. Abstract CT006: Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629
16. KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC).
17. Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling
18. Merkelcellekarsinom.
19. The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review
20. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
21. Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1
22. The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells
23. Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial
24. Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis
25. Ongoing and future clinical trials in particle therapy in the Nordic countries
26. Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.
27. KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
28. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
29. Squamous Cell Carcinoma of the Paranasal Sinuses: A Single Center Experience
30. Treatment of Sinonasal Adenocarcinoma: A Population-Based Prospective Cohort Study
31. Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
32. Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
33. Expression of matrix metalloproteinases and the metastasis-associated gene S100A4 in human neuroblastoma and primitive neuroectodermal tumor cells
34. Squamous Cell Carcinoma of the Paranasal Sinuses: A Single Center Experience.
35. Treatment of Sinonasal Adenocarcinoma: A Population-Based Prospective Cohort Study.
36. Head and neck cancer management in the Nordic countries:an effort to harmonize treatment
37. Abstract CT321: Prevention of cardiac dysfunction during adjuvant breast cancer therapy: the PRADA study
38. Mann med stort hode, lærevansker og multiple basalcellekarsinomer
39. Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer
40. Kardioprotektiv behandling ved adjuvant kreftterapi
41. Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial
42. Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
43. Preoperative radiotherapy in rectal signet-ring cell carcinoma – magnetic resonance imaging and treatment outcome
44. Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
45. Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death
46. Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the Vitamin D3 analog EB 1089
47. Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?
48. Mann med stort hode, lærevanskerog multiple basalcellekarsinomer.
49. Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the Vitamin D3 analog EB 1089
50. The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.